Boston Venture Forum – Ventures
- ImaSight Inc. (formerly Imascope) develops and supplies innovative digital x-ray technology for human and animal healthcare. The company was founded in 2001 to respond to the need for an all-digital x-ray system that delivered hospital-quality images at an affordable price for any size practice. We offer medical professionals, chiropractors and veterinarians the best digital radiography solutions on the market.
ImaSight’s team has the leading-edge expertise necessary to develop a completely new proprietary system for digital imaging. Our collective backgrounds cover a broad range of special
- Prognomix Inc. is a privately held Personalized Medicine company incorporated in Montreal in 2005 and focused on discovery and clinical application of genomic signatures predictive of susceptibility to diseases, their complications and individual therapeutic responsiveness. The company has made significant progress in the identification of the genomic features associated with complications of type II diabetes (T2D). Based on these findings Prognomix has developed a prototype of a molecular diagnostic kit that will include clinical, genomic and epigenomic markers.
- Pediapharm is the ONLY pediatric specialty pharmaceutical company in Canada, providing sales and marketing expertise for the pediatric market segment. Through its network of 2,000 pediatricians and 5,000 pharmacies, Pediapharm’s key objectives are to partner with healthcare entities around the world and bring NEW innovative or existing OTC and Rx pediatric products to the Canadian market.
For more information, please visit http://www.pedia-pharm.com
- The establishment of Biomomentum Inc. is the result of a major restructuring that took place at BioSyntech Canada Inc. For over a decade, the company designed and continuously elaborated on the Mach-1™ and the Arthro-BST™. Dr. Quenneville and Dr. Garon are former employees previously part of the Instrumentation department where they were involved in all business aspects related to the Mach-1™ and the Arthro-BST™. In 2008, the company decided to forego the development and commercialization of these products, due, in part, to a deviation from its core mission. Following an off